



PEARL

## Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis

Parker, Richard; Cabezas, Joaquin; Altamirano, Jose; Arab, Juan Pablo; Ventura-Cots, Meritxell; Sinha, Ashish; Dhanda, Ashwin; Arrese, Marco; McCune, C. Anne; Rowe, Ian A.; Schnabl, Bernd; Mathurin, Phillipe; Shawcross, Debbie; Abraldes, Juan G.; Lucey, Michael R.; Garcia-Tsao, Guadalupe; Verna, Elizabeth; Brown, Robert S.; Bosques-Padilla, Francisco; Vargas, Victor; Louvet, Alexandre; Holt, Andrew P.; Bataller, Ramon

**Published in:**

Clinical Gastroenterology and Hepatology

**DOI:**

[10.1016/j.cgh.2021.01.042](https://doi.org/10.1016/j.cgh.2021.01.042)

**Publication date:**

2021

**Link:**

[Link to publication in PEARL](#)

**Citation for published version (APA):**

Parker, R., Cabezas, J., Altamirano, J., Arab, J. P., Ventura-Cots, M., Sinha, A., Dhanda, A., Arrese, M., McCune, C. A., Rowe, I. A., Schnabl, B., Mathurin, P., Shawcross, D., Abraldes, J. G., Lucey, M. R., Garcia-Tsao, G., Verna, E., Brown, R. S., Bosques-Padilla, F., ... Bataller, R. (2021). Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. *Clinical Gastroenterology and Hepatology*, 0(0). <https://doi.org/10.1016/j.cgh.2021.01.042>

# Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients with Alcoholic Hepatitis

**Richard Parker<sup>1</sup>, Joaquin Cabezas<sup>2,3</sup>, Jose Altamirano<sup>5</sup>, Juan P Arab<sup>6,7</sup>, Meritxell Ventura-Cots<sup>8</sup>, Ashish Sinha<sup>9</sup>, Ashwin Dhanda<sup>10</sup>, Marco Arrese<sup>6,11</sup>, C. Anne McCune<sup>9</sup>, Ian A Rowe<sup>1</sup>, Bernd Schnabl<sup>12</sup>, Phillipe Mathurin<sup>13</sup>, Debbie Shawcross<sup>14</sup>, Juan JG Abraides<sup>15</sup>, Michael R Lucey<sup>16</sup>, Guadalupe Garcia-Tsao<sup>17</sup>, Elizabeth Verna<sup>18</sup>, Robert S Brown Jr<sup>19</sup>, Francisco Bosques-Padilla<sup>20</sup>, Victor Vargas<sup>4</sup>, Alexandre Louvet<sup>13</sup>, Andrew P Holt<sup>21\*</sup>, Ramon Bataller<sup>8\*</sup>**

\*Contributed equally and share senior co-authorship

1. Leeds Liver Unit, St James's University Hospital, Leeds, West Yorkshire, United Kingdom.
2. Department of Gastroenterology and Hepatology, University Hospital Marques de Valdecilla, Valdecilla Research Institute - IDIVAL, Santander, Spain.
3. Departments of Medicine and Nutrition, Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
4. Liver Unit, Hospital Vall d'Hebron, Universitat Autònoma Barcelona, CIBEREHD, Barcelona, Spain.
5. Internal Medicine Department, Hospital Quironsalud, Barcelona, Spain
6. Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
7. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
8. Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA.
9. University Hospitals Bristol NHS Foundation Trust, Marlborough Street, Bristol, United Kingdom.
10. Institute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom.
11. Centro de Envejecimiento y Regeneración (CARE), Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
12. Department of Medicine, VA San Diego Healthcare System, University of California San Diego, La Jolla, CA.
13. Service des Maladies de L'appareil Digestif et Unité INSERM, Hôpital Huriez, Lille, France.
14. Liver Sciences, Dept of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
15. Cirrhosis Care Clinic, Division of Gastroenterology (Liver Unit), CEGIIR, University of Alberta, Edmonton, Canada.
16. Department of Medicine, University of Wisconsin, WI
17. Section of Digestive Diseases, Yale University, New Haven, Connecticut; Section of Digestive Diseases, Department of Veterans Affairs Connecticut Healthcare, West Haven, CT.

18. Division of Digestive and Liver Diseases, Department of Medicine, Columbia College of Physicians and Surgeons, Columbia University Medical Center, New York, NY.

19. Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY.

20. Hospital Sant José Tecnológico de Monterrey. Universidad Autonoma de Nuevo Leon, Monterrey, México.

21. University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, United Kingdom.

**Corresponding Author:**

[richardparker@nhs.net](mailto:richardparker@nhs.net)

Leeds Liver Unit

Merville Building

St James's University Hospital

Beckett Street

Leeds

LS9 7TF

United Kingdom

+44 (0)113 2066704

Dr R Parker is guarantor of this article

**Conflicts of interest:**

RP has received advisory board fees from Sandoz

RB has received consulting fees from Echosens. None of these grants have relationship with the current manuscript.

JC was supported by AEEH (Spanish Association for the Study of the Liver) grant "Juan Rodés 2015"

JA wishes to express his gratitude to the Mexican National Council of Science and Technology (CONACyT, Mexico City, Mexico) for partially supporting his predoctoral stay in Barcelona, Spain.

Other authors report no conflict of interest.

**Financial support:** no specific financial support was received for this work. The INTEAM consortium is supported by funding from the National Institute for Alcohol Abuse and Alcoholism (NIAAA) (1U01AA021908-01).

**Specific author contributions:**

RP developed the idea for this study, collected data, analysed data, drafted and submitted manuscript

JC, JA, JPA, MV-C, AS, AD, MA, AM, IAR, BS, PM, DS, JJGA, MRL, GG-T, EV, RSB, FB-P, VV, APH, RB collected/supervised data collection , reviewed draft manuscript and approved final submission

APH and RB guided the development of the study, reviewed draft manuscripts and approved the final submission

**Word count** (inclusive of main text, references and table/figure legends): 3341

## Abstract

**Background and aims** Alcoholic hepatitis (AH) is a severe condition with poor short-term prognosis. Specific treatment with corticosteroids slightly improves short-term survival but is associated with infection and is not used in many centers. A reliable method to identify patients who will recover spontaneously will minimise the numbers of patients who experience side effects of available treatments.

**Methods** We analysed the trajectory of serum bilirubin concentration over the course of hospital admissions in patients with AH to predict spontaneous survival and the need for treatment.

**Results** data from 426 patients were analysed. Based on bilirubin trajectory, patients were categorized into three groups: 'fast fallers' (bilirubin  $<0.8$  x admission value at day 7), 'static' (bilirubin of  $>0.9 - <1.2$  x admission value) and 'rapid risers' (bilirubin of  $\geq 1.2$  x admission bilirubin). Fast fallers had significantly better 90-day survival compared to other groups (log rank  $p < 0.001$ ), and showed no benefit of corticosteroid therapy (OR for survival at 28 days of treatment, 0.94, 95% CI 0.06 - 8.41). These findings remained even amongst patients with severe disease based on initial DF, GAHS or MELD scores.

**Conclusions** We present an intuitive method of classifying patients with AH based on the trajectory of bilirubin over the first week of admission. It is complimentary to existing scores that identify candidates for corticosteroid treatment or assess response to treatment. This method identifies a group of patients with AH who recover spontaneously and can avoid corticosteroid therapy.

## Keywords

1. Alcoholic hepatitis
2. Outcomes
3. Corticosteroid

Alcoholic hepatitis (AH) is a severe clinical entity characterized by acute onset of jaundice and coagulopathy in patients with alcohol use disorder <sup>1</sup>. The incidence of AH is increasing over recent years <sup>2</sup>. Short-term mortality of AH remains very high globally <sup>3,4</sup>: 15-40% of patients with AH die within 30 days of admission to hospital <sup>5</sup>.

The medical management of AH has not evolved substantially in the last two decades, with multiple potential therapeutic agents tested without a great deal of success <sup>6</sup>. Corticosteroids remain the only established treatment for AH. Although the largest randomised controlled trial of corticosteroids showed only a modest short-term (28-day) survival benefit <sup>5</sup>, a recent network meta-analysis showed a survival benefit <sup>7</sup> but this comes at the cost of a greater risk of infection <sup>5</sup>. There is considerable heterogeneity regarding corticosteroid use amongst physicians with a recent survey of practice showing that a quarter of clinicians did not use corticosteroids in patients with AH <sup>8</sup>.

In contrast to effective treatments, methods to predict prognosis in AH are legion and all perform with a roughly similar degree of accuracy <sup>9-11</sup>. Some of these scores have been used to identify the sub-group of patients who will benefit from corticosteroid therapy, most commonly the discriminant function (DF) <sup>12</sup>, the model for end-stage liver disease (MELD) score and the Glasgow alcoholic hepatitis score (GAHS) <sup>13</sup>. Baseline bilirubin concentration is an important indicator of severity of AH and prognosis in patients with AH, and is included in all scoring systems. The dynamic change in bilirubin over the first days of admission has been identified as an important prognostic indicator <sup>14</sup> and a marker of response to corticosteroid treatment <sup>15</sup>. The Lille model uses change in bilirubin after initiation of prednisolone to gauge response to therapy and guide ongoing treatment and is conventionally applied after seven days of therapy <sup>16</sup> but is also useful after shorter duration of treatment. <sup>17</sup>.

We used computer-aided analysis to study how the trajectory of bilirubin concentration during admission might be useful to identify clinical phenotypes, stratify the probability of short-term survival and guide treatment in a real-world, multi-national observational cohort of patients with AH.

## Patients and Methods

### Study Population, Data Collection and Definitions

Data from consecutive patients were collected prospectively from 3 centers in the UK (University Hospitals Birmingham NHS Foundation Trust (UHB), Birmingham; University Hospitals Bristol NHS Foundation Trust, Bristol; Plymouth Hospital NHS Trust, Plymouth) and from the InTeam consortium (details of participating centers are included in the supplementary material). These cohorts were observational only; no patients underwent treatments or procedures outside the standard of care in each institution.

All patients included had alcoholic hepatitis, defined as a) alcohol use of at least 60 g/d in men and >40 g/d in women for >5 years, b) last drink within four weeks of admission, c) serum bilirubin > 3 mg/dL, d) elevated transaminases >50 and <400 IU/L, e) aspartate transaminase to alanine transaminase ratio >2:1, and f) exclusion of other concomitant liver disease<sup>18</sup>. Liver biopsy was performed only in cases of diagnostic uncertainty, consistent with recent NIAAA guidance for trialists<sup>18</sup>. When biopsy was performed, the histological diagnosis of AH was defined by the presence of hepatocellular damage (hepatocellular ballooning and presence of Mallory bodies), inflammatory infiltrate (predominantly polymorphonuclear cells), and pericellular fibrosis. These criteria are consistent with the INTEAM project inclusion/exclusion criteria (detailed in supplementary data). Baseline (i.e. earliest recorded data after admission to first admitting hospital) clinical and biochemical characteristics, specific treatments for AH and presence of complications during admission (infection or acute kidney injury, AKI) were collected. Clinical complications during admission such as ascites, spontaneous bacterial peritonitis, renal dysfunction, hepatic encephalopathy or gastrointestinal bleeding were treated according to current international guidelines in effect at the time of admission<sup>19-21</sup>.

Bilirubin trajectory across 28 days of admission was analysed in patients who did not receive corticosteroid therapy, using Traj software (<http://www.andrew.cmu.edu/user/bjones/>) in Stata version 15 (StataCorp LLC, Texas, USA). Distinct trajectories were identified that categorised patients into three groups. All other statistical analyses were done in SPSS version 24 (IBM, New York USA).

### Statistical Analysis

The accuracy of predicting bilirubin trajectory at various points within an individual's hospital admission was tested with Kappa values. Groups were compared with t-tests (two group comparisons) or one-way analysis of variance (ANOVA) (for multiple groups). The odds of spontaneous survival at 90 days after admission, i.e. without corticosteroid therapy were calculated for each group and odds ratios calculated based on fast fallers as a reference group. Survival was analysed with Kaplan Meier univariate analysis, and multivariate Cox Proportional hazard analysis to control for multiple factors. Scoring systems (DF, MELD, GAHS, Lille) were calculated as per published data.

To examine the efficacy of corticosteroid use in each group, patients were included if they received corticosteroids after seven or more days of admission to allow for bilirubin trajectory early in admission to be analysed, or if they did not receive corticosteroid therapy. As differences existed between treated and non-treated patients, propensity score matching was used to assemble a comparable cohort. Patients were matched for age, bilirubin concentration, creatinine concentration and albumin concentration, using the SPSS propensity score matching function (**supplementary table I**). To analyse the value of using bilirubin trajectory to predict patient who may not require treatment, risk ratios for survival at 28 days (as per standard outcomes in therapeutic studies) was calculated with or without corticosteroid therapy.



## Results

In total data from 426 patients with AH were collected of whom 317 had a DF above 32 at admission to hospital, and 105 received corticosteroid therapy. The demographic and biochemical characteristics of included patients are depicted in **table I**.

### Identification of bilirubin trajectories

Patients who did not receive corticosteroids (n=321) were used as a modelling group to identify and analyse bilirubin trajectories. Sequential bilirubin values up to 28 days after admission revealed three groups with distinct trajectories of bilirubin concentration over time (**figure 1**): patients with a rapid decrease in bilirubin concentrations ('fast fallers'), patients with bilirubin concentration that remained elevated but without obvious improvement or deterioration ('static') and patients that showed a bilirubin concentration rising inexorably after admission ('rapid risers').

To allow for clinical application of this classification system, the accuracy of using bilirubin observed trajectory at 3 or 7 days after admission to predict subsequent bilirubin trajectory was examined using Kappa values. Groups could not be identified with accuracy at day 3 (Kappa 0.39) but by day 7 bilirubin trajectory over the course of 28 days could be accurately predicted (Kappa 0.92). Accordingly, bilirubin trajectory as assessed at seven days after admission was used for all analyses of clinical utility. Fast fallers had a bilirubin of less than 0.9 x admission value at day 7, the static group had a bilirubin of  $\geq 0.9 - \leq 1.2$  x admission value and rapid risers had a bilirubin  $> 1.3$  x admission value. Importantly, in published trials of corticosteroid therapy in AH the median delay from admission to treatment is 8 days with no association between treatment delay and survival (**supplementary figure 1**), suggesting that a seven day evaluation period is acceptable in hospitalised cases.

The characteristics of each trajectory group are shown in **table I**. A statistically non-significant difference in bilirubin concentration between groups was observed (one-way ANOVA p=0.098), where the highest bilirubin concentration was observed in the static group, with lower bilirubin concentrations in fast faller and rapid risers groups.

## **Fast-falling bilirubin trajectory is associated with spontaneous recovery**

Spontaneous recovery, i.e. survival without corticosteroid therapy at 90-days varied between groups: fast fallers were more likely to recover than patients with static or rising bilirubin concentration (OR 0.54, 95% CI 0.31 – 0.94, and OR 0.39, 95% CI 0.19 – 0.76 respectively) (**table 2, figure 2A**). This remained when severe alcoholic hepatitis was considered defined by GAHS, MELD or DF: in each case, patients with severe disease who had a fast fall in bilirubin had rates of spontaneous recovery comparable to those without severe disease (**figure 2B-D**). After controlling for baseline differences in bilirubin and prothrombin time between groups with Cox proportional hazard analysis, bilirubin trajectory was independently associated with mortality at 90-days ( $p=0.042$ ). Dynamic changes in MELD score between day 1 and day 7, and the Lille score were also predictors of spontaneous recovery.

## **Use of bilirubin trajectory to stratify treatment in alcoholic hepatitis**

To investigate the utility of using bilirubin trajectory to guide treatment, we examined patients who received corticosteroid (CS) treatment *after* seven days of admission, allowing for bilirubin trajectory to be assessed at day 7 before CS therapy. Patients who received corticosteroid therapy after 7 days differed from those who did not (**table 1**), so propensity score matching was used to identify comparable groups. After removing patients who received corticosteroid therapy before seven days of admission and doing propensity score matching, 180 patients were analysed, of whom 90 received corticosteroids and 90 did not.

Corticosteroid therapy had no survival benefit in fast fallers (OR for survival at 28 days of treatment, 0.94, 95% CI 0.06 - 8.41,  $p=0.879$ ). When analysis was limited to patients with severe disease (defined as DF >32, GAHS >8 or MELD >20) this remained the case, with no benefit of corticosteroids observed in each case (**table 3, supplementary figure 2**). Corticosteroid therapy in rapid risers showed a trend towards benefit without reaching statistical significance (OR 4.82, 95% CI 0.85 - 24.4,  $p=0.079$ ). The use of bilirubin trajectory to allow patients with severe disease but a fast falling bilirubin to be managed without corticosteroids would have excluded many patients from treatment: 43% of patients with a DF >32, 45% of patients with a MELD >20 and 45% of patients with a GAHS >8 (**table 1, figure 3**).



## Discussion

This large multi-center, multinational study of patients with AH used computer-assisted analysis of bilirubin trajectory to identify three groups of patients, with distinct clinical phenotypes. A ‘fast falling’ bilirubin trajectory indicated a group of patients who had a greater chance of spontaneous survival and who did not benefit from corticosteroid therapy, even amongst patients with severe disease. Identification of this group of ‘fast fallers’ with a better outcome can allow clinicians confidence to avoid treatment with prednisolone and may facilitate earlier discharge from hospital.

Bilirubin long been identified as important dynamic measure in AH in terms of prognostication<sup>14</sup> and assessing response to treatment<sup>15</sup>. Our data confirm the value of observing this indicator in AH both as a guide to outcome and a guide to therapy. The use of more complex scores – MELD or Lille – over the same seven-day period also gave prognostic information with accuracy comparable to bilirubin alone. This does not detract from the simple observation of the maxim that if patients are getting better, they are likely to continue to improve and liver-specific treatment might be avoided, beyond standard supportive measures.

Importantly the trajectory system is different to the Lille score, as trajectory identifies individuals likely to do well *before* starting treatment with corticosteroids, whereas the Lille score is designed to assess response *after* starting treatment. Indeed, the two scores could be used sequentially in the same patient before and after starting therapy to further minimise futile exposure to corticosteroids. Several scores exist that predict mortality in patients with AH. Bilirubin trajectory does not replace these as a means of prognostication but it can serve as an additional means of identifying patients who may not require corticosteroid therapy despite severe disease. Liver transplantation (LT) for patients who fail to respond to corticosteroid therapy has been shown to be effective in AH<sup>23,24</sup>. ‘Fast fallers’ who are likely to improve without specific treatment are less likely to require LT, and this may influence decision making around patients with severe disease at admission but who display a favourable trajectory of bilirubin.

The observed trajectories of bilirubin concentration that we describe are from the point of hospital admission, rather than from the onset of jaundice. Whilst there are few data to illustrate this, anecdotally there is significant variation in the delay between the onset of jaundice and admission to hospital. The impact of this on observed

trajectories of bilirubin can only be speculated about, but it is conceivable that it is more individuals who become sicker outside of hospital eventually present to medical services, whereas those who improve do not. This variation in presentation may be further complicated by transfer of patients with AH between centers that is common in some health systems, principally in the US. The data used for this study were the earliest available values. The observed trajectories therefore are from the time of admission or very close to it. This may introduce a bias to the observed trajectories when considering AH as a whole, but our findings remain relevant to patients who are admitted to hospital. Further research will illustrate the impact of 'jaundice to door time' and its impact on outcome and observed bilirubin trajectory.

The study has limitations. The research cohort is observational such that the question of the clinical utility of using bilirubin trajectory to guide treatment was not tested specifically. This is a similar technique to derivation of existing scoring systems in AH, and also represents a 'real world' sample where there is known to be marked heterogeneity regarding use of corticosteroids. There may be reasons why certain patients received corticosteroid therapy that were not have been captured and thus introduced bias to the dataset despite propensity score matching. Clinicians eager to start specific therapies may balk at the requirement to observe patients for seven days before patients can be allocated to a group. However, in practice a period of seven days allows for time exclusion of infection, other liver diseases and biopsy if this is felt necessary. We note that the median delay from admission to treatment in the STOPAH trial was 6.7 days, and overall delay in various trials of corticosteroids over the years is more than a week (**supplementary figure 1**). Validation of these observations is key and it is obvious that propensity score matching resulted in a much smaller group than the initial, large cohort.

We used the NIAAA criteria to identify a coherent group of patients to study. These criteria use a bilirubin threshold of 3mg/dL, whereas clinical criteria and histological concordance has only previously been established for higher levels of bilirubin. However in this cohort only a few patients had a bilirubin below 5mg/dL (10 of 321 in the group not treated with corticosteroids and used for model building). Removing this group from the analysis did not result in any meaningful differences in the observations regarding likelihood of survival (data not shown). Lower bilirubin concentrations would make it difficult to understand what small fluctuations may mean,

but this group of patients are unlikely to be considered for corticosteroid therapy in practice.

We present a novel, intuitive method of classifying patients with AH based on the trajectory of bilirubin over the first week of an admission. This system aids in prognostication, but most importantly identifies a group of patients who are likely to have better outcomes and do not benefit from corticosteroid therapy.

## References

1. Lucey, M. R., Mathurin, P. & Morgan, T. R. Alcoholic hepatitis. *New England Journal of Medicine* **360**, 2758-2769 (2009).
2. Sandahl, T. D., Jepsen, P., Thomsen, K. L. & Vilstrup, H. Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: A nationwide population based cohort study. *Journal of hepatology* **54**, 760-764 (2011).
3. Gao, B. & Bataller, R. Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology* **141**, 1572-1585 (2011).
4. Altamirano, J. et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. *Clinical Gastroenterology and Hepatology* **10**, 65-71. e3 (2012).
5. Thursz, M. R. et al. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med* **372**, 1619-1628 (2015).
6. Hughes, E., Hopkins, L. & R, P. Survival from alcoholic hepatitis has not improved over time. *PLoS One* **13**, 1-10 (2018).
7. Singh, S. et al. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. *Gastroenterology* **149**, 958-970.e12 (2015).
8. Dhanda, A., Atkinson, S. & Thursz, M. Variation in the use of corticosteroids for the treatment of acute severe alcoholic hepatitis in the post-STOPAH era: results of a UK national survey. *Journal of Hepatology* **66**, S345 (2017).
9. Ali, S., Hussain, S., Hair, M. & Shah, A. A. Comparison of Maddrey Discriminant Function, Child-Pugh Score and Glasgow Alcoholic Hepatitis Score in predicting 28-day mortality on admission in patients with acute hepatitis. *Ir J Med Sci* **182**, 63-68 (2013).
10. Palaniyappan, N. et al. The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway? *Int J Hepatol* **2012**, 624675 (2012).
11. Sandahl, T. D., Jepsen, P., Ott, P. & Vilstrup, H. Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. *Scand J Gastroenterol* **46**, 1127-1132 (2011).
12. Carithers Jr, R. L. et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. *Annals of internal medicine* **110**, 685 (1989).
13. Forrest, E. H. et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. *Gut* **56**, 1743-1746 (2007).
14. Lee, M. et al. Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis. *PLoS one* **9**, e100870 (2014).
15. Mathurin, P. et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. *Hepatology* **38**, 1363-1369 (2003).
16. Louvet, A. et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology* **45**, 1348-1354 (2007).
17. Garcia-Saenz-de-Sicilia, M. et al. A day-4 Lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis. *The American journal of gastroenterology* **112**, 306 (2017).
18. Crabb, D. W. et al. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the

- NIAAA Alcoholic Hepatitis Consortia. *Gastroenterology* **150**, 785-790 (2016).
19. Garcia-Tsao, G. et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology* **46**, 922-938 (2007).
  20. Moore, K. P. et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. *Hepatology* **38**, 258-266 (2003).
  21. Ferenci, P. et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* **35**, 716-721 (2002).
  22. Louvet, A. et al. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo—a Meta-analysis of Individual Data. *Gastroenterology* (2018).
  23. Mathurin, P. et al. Early liver transplantation for severe alcoholic hepatitis. *New England Journal of Medicine* **365**, 1790-1800 (2011).
  24. Im, G. Y. et al. Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience. *Am J Transplant* **16**, 841-849 (2016).



**Table 1:** characteristics of included patients. Data are presented as mean and standard error of mean except for ^median and interquartile range.

	Entire cohort n=426		Patients without corticosteroid use								p ANOVA
			Modelling cohort n=321		Fast fallers n=150 (47%)		Static n=99 (31%)		Rapid risers n=72 (22%)		
	Average	variance	Average	variance	Average	variance	Average	variance	Average	variance	
Age^ (years)	49.3	10.0	48.5	10.1	47.0	1.0	49.2	1.0	50.3	1.6	0.161
Bilirubin ( $\mu$ mol/L)	271	143	269	139	271	14	296	16	240	19	0.098
Prothrombin time (seconds)	24.2	8.8	23.4	8.38	21.1	0.7	26.1	0.9	25.1	1.4	<b>&lt;0.001**</b>
White Cell Count ( $\times 10^9/L$ )	10.9	6.1	10.9	6.0	10.6	0.6	12.0	0.9	10.3	0.9	0.300
Creatinine (mmol/L)	91.7	78.5	90.2	80.0	88.2	6.3	91.4	8.3	109	0.9	0.378
Sodium (mmol/L)	131	7.1	131	7.6	131	1	131	1	132	1	0.723
Urea (mmol/L)	5.56	13.4	5.56	13.3	7.56	2.30	4.66	0.50	5.20	0.98	0.400

Albumin (g/L)	26.7	6.2	26.9	6.4	26.1	0.8	27.3	0.6	27.5	1.0	0.318
Platelets (x10 <sup>9</sup> /L)	132	82	131	81	149	13	129	8	115	12	0.128
DF >32 n (%)	324 (75%)		243 (75%)		103		85		53		
MELD >20 n (%)	317 (73%)		191 (59%)		86		61		42		
GAHS ≥ 9n (%)	238 (56%)		187 (58%)		84		59		43		

**Table 2:** odds of spontaneous recovery in each trajectory group, analysed with Fisher's exact test

	Odds of spontaneous recovery	Odds ratio	95% CI	p
Fast faller	3.16	1 (reference)		
Static	1.68	0.54	0.30 - 0.93	0.028
Rapid riser	1.32	0.39	0.19 - 0.76	0.005
All non-fast faller	1.61	0.48	0.29 – 0.80	0.005
Improved MELD	3.22	1 (reference)		
Stable MELD	2.20	0.68	0.37 – 1.27	0.2
Deteriorating MELD	1.21	0.38	0.20 – 0.69	0.002
Lille response	9.29	1 (reference)		
Lille partial	2.12	0.23	0.09 – 0.53	0.001
Lille null response	1.02	0.10	0.04 – 0.25	<0.001

**Table 3:** propensity matched analysis of patients treated with or without corticosteroids

	28 day survival				
	Corticosteroids	No corticosteroids	OR	95% CI	p (fishers)
Fast faller	96%	96%	0.94	0.060 - 8.41	0.999
GAHS >8 and fast faller	95%	83%	3.60	0.411 - 31.6	0.416
MELD > 20 and fast faller	91%	88%	1.37	0.208 - 9.02	0.999
DF > 32 and fast faller	96%	96%	1.00	0.086 - 11.6	0.999
	90 day survival				
	Corticosteroids	No corticosteroids	OR	95% CI	p (fishers)
Fast faller	79%	79%	0.99	0.317 - 3.10	0.988
GAHS >8 and fast faller	56%	50%	0.80	0.173 - 3.71	0.776
MELD > 20 and fast faller	62%	65%	1.16	0.352 - 3.84	0.805
DF > 32 and fast faller	76%	75%	0.94	0.292 - 3.01	0.914

## Figure legends

**Figure 1:** differing trajectories of change in serum bilirubin concentration over time after admission with alcoholic hepatitis

**Figure 2** Kaplan Meier analysis of survival after admission to hospital with AH: **A** survival differs between bilirubin trajectory categories (log rank  $p < 0.01$ ). Patients with 'fast falling' bilirubin concentration but with severe disease defined as **B** GAHS above 8, **C** MELD above 20 or **D** discriminant function above 32, have outcomes comparable to non-severe disease (log rank p value: ns, non-significant, \*\*\*  $p < 0.001$ )

**Figure 3:** Identification of patients for with severe disease: bilirubin trajectory analysis identifies a different group of patients with compared to the DF, the GAHS or MELD.